EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myeloid effector cells in cancer

Pieter Schol, Marit J van Elsas, Jim Middelburg, Maarten K Nijen Twilhaar, Thorbald van Hall, Tetje C van der Sluis, Sjoerd H van der Burg

Cancer Cell · 2024-12 · 42 (12) · 1997-2014

DOI: 10.1016/j.ccell.2024.11.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von Pieter Schol und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Immunotherapy, Myeloid Cells, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding, Health~Holland, Oncode Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of myeloid cells in tumor immunity is multifaceted. While dendritic cells support T cell-mediated tumor control, the highly heterogenous populations of macrophages, neutrophils, and immature myeloid cells were generally considered immunosuppressive. This view has led to effective therapies reinvigorating tumor-reactive T cells; however, targeting the immunosuppressive effects of macrophages and neutrophils to boost the cancer immunity cycle was clinically less successful. Recent studies interrogating the role of immune cells in the context of successful immunotherapy affirm the key role of T cells, but simultaneously challenge the idea that the cytotoxic function of T cells is the main contributor to therapy-driven tumor regression. Rather, therapy-activated intra-tumoral T cells recruit and activate or reprogram several myeloid effector cell types, the presence of which is necessary for tumor rejection. Here, we reappreciate the key role of myeloid effector cells in tumor rejection as this may help to shape future successful immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMyeloid CellsNeoplasmsAnimalsHumansDendritic CellsMacrophagesNeutrophilsT-LymphocytesTumor Microenvironment

Stichwörter der Autor:innen

M1 macrophagescancer immunity cycleeosinophilsimmunotherapymyeloid cellsneutrophils

Autor:innen und Institutionen

  • Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: s.h.van_der_burg@lumc.nl.

Förderung

  • KWF Kankerbestrijding
  • Health~Holland
  • Oncode Institute

Zitieren

APA

Schol, P., van Elsas, M. J., Middelburg, J., Nijen Twilhaar, M. K., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024). Myeloid effector cells in cancer. Cancer Cell, 42(12), 1997-2014. https://doi.org/10.1016/j.ccell.2024.11.002

Vancouver

Schol P, van Elsas MJ, Middelburg J, Nijen Twilhaar MK, van Hall T, van der Sluis TC, et al. Myeloid effector cells in cancer. Cancer Cell. 2024;42(12):1997-2014. doi:10.1016/j.ccell.2024.11.002

BibTeX
@article{Schol2024,
  author = {Schol, Pieter and van Elsas, Marit J and Middelburg, Jim and Nijen Twilhaar, Maarten K and van Hall, Thorbald and van der Sluis, Tetje C and van der Burg, Sjoerd H},
  title = {Myeloid effector cells in cancer},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {1997--2014},
  doi = {10.1016/j.ccell.2024.11.002}
}
Kostenlos starten →